Sano, Tyler
Losakul, Ravipa
Schmidt, Holger
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NIH RM1 HG011543)
United States Department of Defense | United States Army | U.S. Army Research, Development and Engineering Command | Army Research Office (W911NF-17-1-0469)
National Science Foundation (CBET-1703058)
Article History
Received: 14 March 2023
Accepted: 12 September 2023
First Online: 6 October 2023
Competing interests
: H. Schmidt had a financial interest in Fluxus Inc., which commercializes optofluidic technology. H. Schmidt declares no nonfinancial competing interest. T. Sano and R. Losakul declare no competing interests.